EUCTR2006-000028-15-IT进行中（未招募）不适用
A randomised, open label, parallel-group, multi-centre trial to compare the efficacy and safety of TachoSil versus standard haemostatic treatment in cardiovascular surgery - TachoSil versus standard haemostatic treatment of haemorrhage in cardiovascular surgery
YCOMED HEADQUARTER0 个研究点目标入组 1,200 人开始时间: 2007年2月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All inclusion criteria must be answered yes for a subject to participate in the trial. At Screening 1.Has the subject given informed consent according to local requirements before any trial related activities A trial related activity is any procedure that would not have been performed during the routine management of the subject. In this trial the screening is the first trial related activity. 2.For female subjects of childbearing potential Is the pregnancy test at screening negative 3.Does the female subject of child-bearing potential use adequate contraception contraceptive pill, contraceptive injection, contraceptive implant or intrauterine device 4.Is the subject major or equal 18 years of age 5.Is the following planned An elective surgery on the heart, the ascending aorta or arch, requiring cardiopulmonary bypass procedure Intra operative after primary haemostatic treatment 6.Is bleeding from the heart muscle, the pericardium, a major vessel or a vascular bed that requires supportive haemostatic treatment present 7.Has the area with the most problematic haemorrhage target area been identified please note that this must be done before randomisation . 8.Is it possible to compress the randomised treatment TachoSil or control fleece material for 3 minutes
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •All exclusion criteria must be answered no for a subject to participate in the trial. At Screening 1.Has the subject participated in any other trial with an investigational drug or device within 30 days before inclusion in this trial 2.Does the subject participate in a clinical trial concomitantly with the present trial 3.Is the subject undergoing an emergency operation 4.Has the subject a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin 5.Is the subject suffering from known coagulopathy 6.Is the subject currently participating or has the subject previously participated in the TC-023-IM trial 7.Is the female subject pregnant or breast feeding Intra operative after primary haemostatic treatment 8.Has liquid fibrin sealant/glue or TachoSil been applied 9.Has the following occurred Disseminated intravascula
研究者
相似试验
进行中（未招募）
不适用
A randomised, open label, parallel-group, multi-centre trial to compare the efficacy and safety of TachoSil versus standard haemostatic treatment in the cardiovascular surgery - TachoSil versus standard haemostatis treatment of haemorrhage in cardiovascular surgerySupportive haemostatic treatment in patients having elective surgery on the heart, the ascending aorta or arch, requiring pulmonary bypass procedure.EUCTR2006-000028-15-DEycomed Danmark ApS1,200
进行中（未招募）
不适用
A randomised, open label, parallel-group, multi-centre trial to compare the efficacy and safety of TachoSil versus standard haemostatic treatment in the cardiovascular surgery - TachoSil versus standard haemostatis treatment of haemorrhage in cardiovascular surgeryEUCTR2006-000028-15-DKycomed Danmark ApS1,200
进行中（未招募）
1 期
A randomised, open label, parallel-group, multi-centre trial to compare the efficacy and safety of TachoSil versus standard haemostatic treatment in the cardiovascular surgery - TachoSil versus standard haemostatis treatment of haemorrhage in cardiovascular surgerySupportive haemostatic treatment in patients having elective surgery on the heart, the ascending aorta or arch, requiring pulmonary bypass procedure.EUCTR2006-000028-15-FRycomed Danmark ApS1,200
进行中（未招募）
不适用
A randomised, open-label, parallel-group, multi-centre trial comparing the efficacy and safety of 12 months treatment with one daily dose of ZOMACTON® to one daily dose of GENOTROPIN® in the treatment of children with idiopathic growth hormone deficiencyIdiopathic growth hormone deficiency.MedDRA version: 9.1Level: LLTClassification code 10056438Term: Growth hormone deficiencyEUCTR2008-004849-28-HUFerring Pharmaceuticals A/S138
已完成
3 期
A Study of Zomacton in Children with Growth Hormone Deficiency.CTRI/2011/04/001669Ferring Pharmaceuticals138